Funding & Business initiatives
Hadasit Bio-Holdings Ltd. (HBL) was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) to allow public participation in academically originated biotechnology innovations.
It is a precedent-setting model. For the first time, the public can invest in companies based on IP generated by the Hadassah University Hospital. HBL traded shares are a unique vehicle for investing in a portfolio of biotech companies all based on inventions developed and owned by Hadassah
Hadasit has partnered with the NGT HealthCare II
venture capital fund to establish a $30M incubator fund
backed by the Israel Innovation Authority, to support
seed-stage startups, from Hadassah and elsewhere,
and bridge the gap between academia and industry.
Hadasit is the technology transfer company for Azrieli College’s healthcare-related intellectual property. We bring together Hadassah’s clinical experts and the best engineering minds at Azrieli to create viable new projects in various fields: including bio convergence, bioengineering, medical device and more.
Hadassah researchers interested in collaboration with Azrieli college engineers are welcome to contact VP of Medical Device Business Development at Hadasit